Skip to main content
Premium Trial:

Request an Annual Quote

Syrrx Opens New San Diego Drug Discovery Center, Hires Two Chemists

NEW YORK, Aug. 7-Syrrx has opened an 84,000-square-foot structural biology, combinatorial chemistry and nanotechnology center in San Diego, the company said today.


The new center, which can house about 250 researchers, centralizes Syrrx's drug discovery programs and provides room for the company to expand.


Former GlaxoSmithKline chemical oncology director Jeffrey Stafford will manage the discovery chemistry and medicinal chemistry programs at the new research center.


DuPont and CombiChem veteran Daniel Kassel will be senior director of analytical technologies, overseeing company development of drug discovery technology.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.